Investigating Reactive Astrocytosis in Alzheimer's Disease Using [18F]Fluorodeprenyl‐D2 PET Imaging

Background Alzheimer's Disease (AD) is often accompanied by neuroinflammation, which manifests prior to significant cognitive decline. Reactive astrocytosis is a hallmark of such inflammation, potentially serving as an early biomarker for AD pathology. Our study employs [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron emission tomography (PET) imaging to in vivo quantify astrocytosis comparing AD with healthy controls and examines its assocciation with cognitive deterioration in AD. Method Our cross‐sectional study involved 12 early‐stage Alzheimer's Disease (AD) patients and 11 healthy controls, all undergoing [18F]F‐DED and MRI imaging. AD diagnosis was based on CSF amyloid‐β42/40 ratios under 5.5% and MMSE scores below 27, while controls had MMSE scores above 27 with no amyloid‐β pathology. We assessed differences in [18F]F‐DED uptake using ROI‐based analyses, processing data in PMOD software. This involved calculating the radioligand's volume of distribution in tissues and image‐derived plasma at equilibrium. For ROI analysis, we adapted the Automated Anatomical Labeling (AAL) atlas to each participant's gray matter masks and [18F]F‐DED maps, computing median uptake values per ROI. Cortical amyloid deposition was measured using [18F]flutemetamol β‐amyloid‐PET imaging. CSF biomarkers, including Aβ42, Aβ40, and phosphorylated tau, were analyzed using the Lumipulse G1200 platform. Cognitive performance was evaluated with the MMSE. We used ANCOVA and linear regression in R to explore correlations between cognitive performance and [18F]F‐DED uptake, adjusting for age and sex. Results Increased [18F]F‐DED uptake was observed in AD‐affected areas comparing AD with controls, particularly in the bilateral occipital (Left: T:2.28, p=0.03; Right: T:2.51, p=0.02), temporal (Left: T:2.21, p=0.03; Right: T‐Stat 2.22, p=0.03), and frontal lobes (Left: T:2.46, p